Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 17/20 | 0.37 |
| ▸ | TP53 | P04637 | 7/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753545 | 0.68 | KCNA5 (0.56) | MDM2TP53MEN1KMT2AKCNA5 | |
| SCHEMBL3751626 | 0.61 | KCNA5 (0.47) | MDM2TP53MEN1KMT2AKCNA5 | |
| SCHEMBL3750562 | 0.61 | KCNA5 (0.47) | MDM2TP53MEN1KMT2AKCNA5 | |
| SCHEMBL3756429 | 0.61 | KCNA5 (0.47) | MDM2TP53MEN1KMT2AKCNA5 | |
| SCHEMBL2665746 | 0.60 | TSHR (0.73) | — | |
| SCHEMBL19441240 | 0.58 | HPGD (0.47) | MEN1KMT2A | |
| SCHEMBL8174236 | 0.57 | NAAA (0.67) | — | |
| SCHEMBL19441193 | 0.56 | HDAC3 (0.41) | MEN1KMT2A | |
| SCHEMBL3756729 | 0.56 | ALDH1A1 (0.40) | MDM2TP53MEN1KMT2AKCNA5 | |
| SCHEMBL1826342 | 0.56 | MDM2 (1.00) | MDM2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |